CELTAXSYS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.celtaxsys.com
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03964558
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02443688
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Drexel University, Philadelphia, Pennsylvania, United States
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02385760
- Locations
- 🇦🇺
Central Sydney Dermatology, Sydney, New South Wales, Australia
🇦🇺Fremantle Dermatology, Fremantle, Western Australia, Australia
🇳🇿Optimal Clinical Trials, Auckland, New Zealand
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02233244
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01944735
- Locations
- 🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom
🇬🇧The Medicinces Evaluation Unit, Wythenshawe, Manchester, United Kingdom
🇬🇧Celerion, Belfast, Northern Ireland, United Kingdom
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT01748838
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
© Copyright 2024. All Rights Reserved by MedPath